Frost & Sullivan Confers European Biopharmaceuticals Company of the Year Award on Debiopharm Group(TM)

By Frost Sullivan, PRNE
Tuesday, November 30, 2010

LONDON, December 1, 2010 - The 2010 Frost & Sullivan Europe Company of the Year Award in
Biopharmaceuticals is presented to Debiopharm Group(TM) (Debiopharm).


Debiopharm has a business model of in-licensing new molecules from
biotech companies, pharmaceutical and start up companies as well as academic
institutions based worldwide. It then adds value through a creative
development strategy. Towards the end of the development process, it
out-licenses the developed and registered drugs to pharmaceutical firms for
worldwide commercialisation.

"The company specialises in the drug development process, successfully
bringing novel biopharmaceuticals to market," notes Frost & Sullivan Industry
Analyst Ranjith Gopinathan. "By independently funding the worldwide
development of its products, Debiopharm is able to excel in drug

To date, Debiopharm has successfully developed five products. These
include Eloxatin(R)/ Elplat(R) for the treatment of colorectal cancer,
Decapeptyl(R)/Trelstar(R)/Pamorelin(R) of different formulations for the
palliative treatment of advanced prostate cancer, endometriosis, uterine
fibromyomas, precocious puberty, female infertility (part of the in vitro
fertilisation program), breast cancer and ovarian cancer, and
Moapar(R)/Salvacyl(R) for the treatment of severe sexual deviations.

The lead products Decapeptyl(R)/Trelstar(R) and Eloxatin(R) are among the
key products of its commercial partners. Debiopharm has built synergistic
partnerships with a wide range of biotechnology, pharmaceutical and academic
organisations including Ache, Aurigene, CAT, Dr. Reddy's Laboratories,
Ferring, Ipsen, Kirin, LG Life Sciences, Nagoya-City University, NanoCarrier,
Novartis, Pfizer, Pharmaleads, Ranbaxy, Rowfarma, Salix, Sanofi-Aventis,
Sidus, TcLand, Tecnofarma, Tulane University, Yakult and Watson

Debiopharm has a good mix of pipeline products in various phases of
clinical trials. Its key pipeline candidates are Debio 8206 for
Hormone-dependent prostate cancer, which has successfully been submitted for
approval and is now commercialized in many key markets, as well as Debio 025
(licensed to Novartis worldwide, except Japan) for hepatitis C virus (HCV)
and Debio 0932 expected to be licensed for an oncology indication, both of
which are at an advanced stage of clinical trials.

"By maximising the commercial potential of its partnered therapeutic
products, Debiopharm is able to provide leadership to its partners and
customers," remarks Gopinathan. "Moreover, it reinvests the commercial
returns into the development of a new generation of products for its
customers, underlining its commitment to continuous product innovation."

Each year, this Award is presented to the company that has excelled in
the following criteria: growth strategy excellence, growth implementation
excellence, degree of innovation with products and technologies and
leadership in customer value.

Frost & Sullivan Best Practices Awards recognise companies in a variety
of regional and global markets for demonstrating outstanding achievement and
superior performance in areas such as leadership, technological innovation,
customer service, and strategic product development. Industry analysts
compare market participants and measure performance through in-depth
interviews, analysis, and extensive secondary research in order to identify
best practices in the industry.

About Debiopharm Group

Debiopharm Group is a Swiss-based biopharmaceutical group of companies
with a focus on the development of prescription drugs that target unmet
medical needs. It was founded in 1979 and is headquartered in Lausanne,

The group in-licenses, develops and/or co-develops promising biological
and small molecule drug candidates having reached clinical development phases
I, II or III. Oncology is the group's main area of expertise. In addition,
Debiopharm Group develops or co-develops drugs for specific indications, such
as infectious diseases, neurodegenerative disorders, pain, metabolic diseases
and immune-mediated diseases. Debiopharm, independently funds the worldwide
development of all of its products, while providing expertise in pre-clinical
and clinical trials, manufacturing, drug delivery and formulation, and
regulatory affairs.

It has a team of 300 professionals from over 20 different countries.
Moreover, Debiopharm is advised by a network of international consultants
with scientific expertise in all relevant areas.

About Frost & Sullivan

Frost & Sullivan, the Growth Partnership Company, enables clients to
accelerate growth and achieve best-in-class positions in growth, innovation
and leadership. The company's Growth Partnership Service provides the CEO and
the CEO's Growth Team with disciplined research and best-practice models to
drive the generation, evaluation, and implementation of powerful growth
strategies. Frost & Sullivan leverages over 45 years of experience in
partnering with Global 1000 companies, emerging businesses and the investment
community from 40 offices on six continents. To join our Growth Partnership,
please visit


    Emily Bailey
    Events & Promotions Co-ordinator
    Frost & Sullivan

Emily Bailey, Events & Promotions Co-ordinator of Frost & Sullivan, +4420-7915-7869

will not be displayed